Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Utilizing AI for individualized treatment-adjusted risk stratification in newly diagnosed myeloma

Gareth Morgan • 11 Dec 2022
ASH 2022
Multiple Myeloma

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, discusses how artificial intelligence (AI) can be used to create an individualized prediction model for patients with newly diagnosed multiple myeloma. Prof. Morgan explains that the model is able to capture the interaction of genomic, clinical and therapy factors, to ultimately enable more efficient tailored therapeutic decisions in multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gareth Morgan

2:19
How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
Gareth Morgan • 10 Dec 2023
1:48
Investigating the non-coding myeloma genome
Gareth Morgan • 10 Dec 2023
1:29
Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma
Gareth Morgan • 10 Dec 2023
1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals